BACKGROUND: We evaluated the disease management programme (DMP) "Therapie Aktiv" for diabetes mellitus type 2 during the first year of implementation in a cluster-randomised controlled trial (RCT), which revealed an improvement of process quality, but only insignificant effects on HbA1c. To further analyse the effects of the DMP we followed up participants of the RCT for another year. METHODS: After completion of the RCT, the study was continued as an open observational trial. By patient's choice, three groups were formed. Group 1 (DMP/DMP): interventions of the RCT (DMP), who remained in the DMP; group 2 (Control/DMP): controls of the RCT (usual care), who participated in the DMP during the second year; group 3 (Control/Control): controls of the RCT (usual care), who remained as controls. PRIMARY OUTCOME MEASURE: HbA1c. SECONDARY OUTCOME MEASURES: BMI, lipids, blood pressure and measures of process quality. RESULTS: Only 801 of 1,489 RCT participants completed the study (53.8 %). Group 1: n = 355; group 2: n = 335; group 3: n = 111. After 2 years, pre-post-analysis revealed a significant reduction of HbA1c (0.37 %, p < 0.001) in both DMP groups, and a reduction of only 0.03 % (p = 0.975) in the control group. However, the difference between the groups was not significant (p = 0.065). There was a significant improvement of process quality in the DMP groups compared with controls. CONCLUSION: The DMP clearly enhances process quality. Furthermore, the DMP yields a reduction of HbA1c within groups after 2 years, but significance is lost in between-group analysis. We conclude that the DMP has only a minor effect on metabolic control.
RCT Entities:
BACKGROUND: We evaluated the disease management programme (DMP) "Therapie Aktiv" for diabetes mellitus type 2 during the first year of implementation in a cluster-randomised controlled trial (RCT), which revealed an improvement of process quality, but only insignificant effects on HbA1c. To further analyse the effects of the DMP we followed up participants of the RCT for another year. METHODS: After completion of the RCT, the study was continued as an open observational trial. By patient's choice, three groups were formed. Group 1 (DMP/DMP): interventions of the RCT (DMP), who remained in the DMP; group 2 (Control/DMP): controls of the RCT (usual care), who participated in the DMP during the second year; group 3 (Control/Control): controls of the RCT (usual care), who remained as controls. PRIMARY OUTCOME MEASURE: HbA1c. SECONDARY OUTCOME MEASURES: BMI, lipids, blood pressure and measures of process quality. RESULTS: Only 801 of 1,489 RCT participants completed the study (53.8 %). Group 1: n = 355; group 2: n = 335; group 3: n = 111. After 2 years, pre-post-analysis revealed a significant reduction of HbA1c (0.37 %, p < 0.001) in both DMP groups, and a reduction of only 0.03 % (p = 0.975) in the control group. However, the difference between the groups was not significant (p = 0.065). There was a significant improvement of process quality in the DMP groups compared with controls. CONCLUSION: The DMP clearly enhances process quality. Furthermore, the DMP yields a reduction of HbA1c within groups after 2 years, but significance is lost in between-group analysis. We conclude that the DMP has only a minor effect on metabolic control.
Authors: Kevin Knight; Enkhe Badamgarav; James M Henning; Vic Hasselblad; Anacleto D Gano; Joshua J Ofman; Scott R Weingarten Journal: Am J Manag Care Date: 2005-04 Impact factor: 2.229
Authors: Susan L Norris; Phyllis J Nichols; Carl J Caspersen; Russell E Glasgow; Michael M Engelgau; Leonard Jack; George Isham; Susan R Snyder; Vilma G Carande-Kulis; Sanford Garfield; Peter Briss; David McCulloch Journal: Am J Prev Med Date: 2002-05 Impact factor: 5.043
Authors: Elizabeth Selvin; Spyridon Marinopoulos; Gail Berkenblit; Tejal Rami; Frederick L Brancati; Neil R Powe; Sherita Hill Golden Journal: Ann Intern Med Date: 2004-09-21 Impact factor: 25.391
Authors: Ivo Rakovac; Johannes Plank; Klaus Jeitler; Peter Beck; Sabine Seereiner; Peter Mrak; Bernd Bauer; Thomas R Pieber Journal: Wien Med Wochenschr Date: 2009
Authors: Joshua J Ofman; Enkhe Badamgarav; James M Henning; Kevin Knight; Anacleto D Gano; Rebecka K Levan; Shoval Gur-Arie; Margaret S Richards; Vic Hasselblad; Scott R Weingarten Journal: Am J Med Date: 2004-08-01 Impact factor: 4.965
Authors: Andreas C Sönnichsen; Henrike Winkler; Maria Flamm; Sigrid Panisch; Peter Kowatsch; Gert Klima; Bernhard Fürthauer; Raimund Weitgasser Journal: BMC Fam Pract Date: 2010-11-05 Impact factor: 2.497
Authors: Endre Szigethy; Zoltán Jancsó; Csaba Móczár; István Ilyés; Eszter Kovács; László Róbert Kolozsvári; Imre Rurik Journal: Wien Klin Wochenschr Date: 2013-07-04 Impact factor: 1.704
Authors: Tim Johansson; Sophie Keller; Henrike Winkler; Thomas Ostermann; Raimund Weitgasser; Andreas C Sönnichsen Journal: J Diabetes Res Date: 2015-12-20 Impact factor: 4.011
Authors: Brenda W C Bongaerts; Karsten Müssig; Johan Wens; Caroline Lang; Peter Schwarz; Michael Roden; Wolfgang Rathmann Journal: BMJ Open Date: 2017-03-20 Impact factor: 2.692
Authors: Loraine Busetto; Katrien Luijkx; Stefano Calciolari; Laura Guadalupe González Ortiz; Hubertus Johannes Maria Vrijhoef Journal: Int J Integr Care Date: 2018-06-01 Impact factor: 5.120
Authors: Loraine Busetto; Katrien Ger Luijkx; Arianne Mathilda Josephus Elissen; Hubertus Johannes Maria Vrijhoef Journal: BMC Health Serv Res Date: 2016-01-15 Impact factor: 2.655